L18 L19

L20

L21

L22

(FILE 'HOME' ENTERED AT 15:15:06 ON 17 JUL 2002) FILE 'REGISTRY' ENTERED AT 15:15:36 ON 17 JUL 2002 L11 S 9030-45-9/RN L21 S 3416-24-8/RN L3 1 S 3616-42-0/RN FILE 'HCAPLUS' ENTERED AT 15:19:08 ON 17 JUL 2002 FILE 'REGISTRY' ENTERED AT 15:19:32 ON 17 JUL 2002 SET SMARTSELECT ON L4SEL L1 1- CHEM: 17 TERMS SET SMARTSELECT OFF FILE 'HCAPLUS' ENTERED AT 15:19:33 ON 17 JUL 2002 L5 447 S L4 FILE 'REGISTRY' ENTERED AT 15:19:39 ON 17 JUL 2002 SET SMARTSELECT ON L6 SEL L2 1- CHEM: 12 TERMS SET SMARTSELECT OFF FILE 'HCAPLUS' ENTERED AT 15:19:40 ON 17 JUL 2002 L7 19304 S L6 FILE 'REGISTRY' ENTERED AT 15:19:46 ON 17 JUL 2002 SET SMARTSELECT ON L8 SEL L3 1- CHEM: 6 TERMS SET SMARTSELECT OFF FILE 'HCAPLUS' ENTERED AT 15:19:47 ON 17 JUL 2002 L9 620 S L8 L10 167 S L5 (L) L7 (L) L9 L11 119 S L10 AND PD<19970114 L12 605 S L7 (L) PREP/RL L13 32 S L9 (L) PREP/RL L14 134 S L5 (L) (L11 OR L12) L15 17 S L5 (L) L11 (L) L12 L16 122 S L14 AND PD<19970114 0 S L16 AND FERMENT? L17

3 S L14 (L) FERMENT?

3 S L19 (L) L5

122 S L16

190 S FERMENT? (L) (L7 OR L9)

7 S L21 AND INHIBIT? AND PRODUCT

=> d'ibib ab 1-3

L20 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:634531 HCAPLUS

DOCUMENT NUMBER: 136:258038

TITLE: Analysis of the chromosome sequence of the legume

symbiont Sinorhizobium meliloti strain 1021

AUTHOR(S): Capela, Delphine; Barloy-Hubler, Frederique; Gouzy,

Jerome; Bothe, Gordana; Ampe, Frederic; Batut,

Jacques; Boistard, Pierre; Becker, Anke; Boutry, Marc; Cadieu, Edouard; Dreano, Stephane; Gloux, Stephanie; Godrie, Therese; Goffeau, Andre; Kahn, Daniel; Kiss, Erno; Lelaure, Valerie; Masuy, David; Pohl, Thomas;

Portetelle, Daniel; Puhler, Alfred; Purnelle, Benedicte; Ramsperger, Ulf; Renard, Clotilde; Thebault, Patricia; Vandenbol, Micheline; Weidner,

Stefan; Galibert, Francis

CORPORATE SOURCE: Laboratoire de Biologie Moleculaire des Relations

> Plantes-Microorganismes, Unite Mixte de Recherche (UMR) 215 Centre National de la Recherche Scientifique (CNRS), Institut National de la Recherche Agronomique,

Chemin, Tolosan, F-31326, Fr.

SOURCE: Proceedings of the National Academy of Sciences of the

United States of America (2001), 98(17), 9877-9882

CODEN: PNASA6; ISSN: 0027-8424 National Academy of Sciences

PUBLISHER: DOCUMENT TYPE: Journal

LANGUAGE: English

Sinorhizobium meliloti is an .alpha.-proteobacterium that forms agronomically important N2-fixing root nodules in legumes. We report here the complete sequence of the largest constituent of its genome, a 62.7% GC-rich 3654,135-bp circular chromosome. Annotation allowed assignment of a function to 59% of the 3341 predicted protein-coding ORFs, the rest exhibiting partial, weak, or no similarity with any known sequence. Unexpectedly, the level of reiteration within this replicon is low, with only two genes duplicated with more than 90% nucleotide sequence identity. transposon elements accounting for 2.2% of the sequence, and a few hundred short repeated palindromic motifs (RIME1, RIME2, and C) widespread over the chromosome. Three regions with a significantly lower GC content are most likely of external origin. Detailed annotation revealed that this replicon contains all housekeeping genes except two essential genes that are located on pSymB. Amino acid/peptide transport and degrdn. and sugar metab. appear as two major features of the S. meliloti chromosome. The presence in this replicon of a large no. of nucleotide cyclases with a peculiar structure, as well as of genes homologous to virulence determinants of animal and plant pathogens, opens perspectives in the study of this bacterium both as a free-living soil microorganism and as a plant symbiont.

REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2002 ACS

2000:68590 HCAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 132:121532

TITLE: Glucosamine fermentation with recombinant

microorganisms with mutations in the

glucosamine-6-phosphate metabolic pathway

Berry, Alan; Burlingame, Richard P.; Millis, James R.

PATENT ASSIGNEE(S): DCV, Inc. D/B/A Bio-Technical Resources, USA SOURCE:

PCT Int. Appl., 151 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

INVENTOR(S):

```
WO 2000004182
                     A1 20000127
                                          WO 1999-US15976 19990715
        W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
             DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
             JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
             MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
             TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD,
             RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
             ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
             CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     US 6372457
                     В1
                           20020416
                                        US 1998-115475
                                                           19980715
     AU 9951028
                      A1
                           20000207
                                          AU 1999-51028
                                                           19990715
     EP 1095158
                      A1
                           20010502
                                         EP 1999-935577
                                                           19990715
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
                      T2 20020709
     JP 2002520067
                                          JP 2000-560279
                                                           19990715
PRIORITY APPLN. INFO.:
                                       US 1998-115475 A 19980715
                                       US 1997-35494P
                                                      P 19970114
                                       WO 1998-US800
                                                        A2 19980114
                                       WO 1999-US15976 W 19990715
     The present invention relates to a method and materials for producing
AB
     glucosamine by fermn. of a genetically modified
     microorganism. Included in the present invention are genetically modified
     microorganisms useful in the present method for producing
     glucosamine, as well as recombinant nucleic acid mols. and the
     proteins produced by such recombinant nucleic acid mols. Thus, a modified
     Escherichia coli strain with the nagA-D genes deleted, the manXYZ genes
     mutationally inactivated, and the glmS gene replaced with an inducible
     mutant glmS gene encoding a glucosamine-6-
     phosphate synthase resistant to glucosamine-
     6-phosphate inhibition was constructed. In
     fermentor cultures, glucosamine concns. in excess of 12
     g/L were obtained with this E. coli strain.
REFERENCE COUNT:
                              THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
                        5
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
L20 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER:
                        1998:493700 HCAPLUS
DOCUMENT NUMBER:
                        129:121714
TITLE:
                        Process for production of N-glucosamine
INVENTOR(S):
                        Berry, Alan; Burlingame, Richard P.; Millis, James R.
PATENT ASSIGNEE(S):
                        Bio-Technical Resources, USA; Berry, Alan; Burlingame,
                        Richard P.; Millis, James R.
SOURCE:
                        PCT Int. Appl., 91 pp.
                        CODEN: PIXXD2
DOCUMENT TYPE:
                        Patent
LANGUAGE:
                        English
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
     PATENT NO.
                                         APPLICATION NO. DATE
                     KIND DATE
                                          -----
     WO 9830713
                     A1 19980716
                                         WO 1998-US800 19980114
         W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,
             KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
             NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
             UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
             FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
             GA, GN, ML, MR, NE, SN, TD, TG
     AU 9859604
                      A1 19980803
                                          AU 1998-59604
                                                           19980114
     US 6372457
                      B1
                           20020416
                                          US 1998-115475
                                                           19980715
PRIORITY APPLN. INFO.:
                                       US 1997-35494P P 19970114
                                                      W 19980114
                                       WO 1998-US800
AB
     The present invention relates to a method for producing glucosamine by
```

• fermn. of a genetically modified microorganism.

=> d ibib ab 1-7

L22 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 1997:392564 HCAPLUS

DOCUMENT NUMBER: 127:47021

TITLE: Substrate binding is required for assembly of the

active conformation of the catalytic site in Ntn

amidotransferases: evidence from the 1.8 .ANG. crystal

structure of the glutaminase domain of

glucosamine 6-phosphate

synthase. [Erratum to document cited in

CA125:136326]

AUTHOR(S): Isupov, Michail N.; Obmolova, Galya; Butterworth,

Susanna; Badet-Denisot, Maria-Ange; Badet, Bernard; Polikarpov, Igor; Littlechild, Jennifer A.; Teplyakov,

Alexei

Dep. Chem. Biological Scis., Univ. Exeter, Exeter, EX4 CORPORATE SOURCE:

4QD, UK

SOURCE: Structure (London) (1997), 5(5), 723

CODEN: STRUE6; ISSN: 0969-2126

PUBLISHER: Current Biology

DOCUMENT TYPE: Journal LANGUAGE: English

The catalytic mechanism described for glucosamine 6-

phosphate synthase was based on the mechanism of penicillin hydrolysis by penicillin acylase proposed by Duggleby et al. (1995) to which ref. should have been made: Duggleby, H.J., Tolley, S.P., Hill, C.P., Dodson, E.J., Dodson, G. and Moody, P.C.E. (1995) Nature 373,

264-268.

L22 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2002 ACS 1996:460296 HCAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 125:136326

TITLE: Substrate binding is required for assembly of the

active conformation of the catalytic site in Ntn amidotransferases: evidence from the 1.8 .ANG. crystal

structure of the glutaminase domain of

glucosamine 6-phosphate

synthase

AUTHOR(S): Isupov, Michail N.; Obmolova, Gayla; Butterworth,

Susanna; Badet-Denisot, Marie-Ange; Badet, Bernard; Polikarpov, Igor; Littlechild, Jennifer A.; Teplyakov,

Alexei

CORPORATE SOURCE: Dep. Chem. Biological Scis., Univ. Exeter, Exeter, EX4

4QD, UK

SOURCE: Structure (London) (1996), 4(7), 801-810

CODEN: STRUE6; ISSN: 0969-2126

DOCUMENT TYPE: Journal LANGUAGE: English

Amidotransferases use the amide nitrogen of glutamine in a no. of important biosynthetic reactions. They are composed of a glutaminase domain, which catalyzes the hydrolysis of glutamine to glutamate and ammonia, and a synthetase domain, catalyzing amination of the substrate. To gain insight into the mechanism of nitrogen transfer, we examd. the

structure of the glutaminase domain of glucosamine 6phosphate synthase (GLMS). The crystal structures of the enzyme complexed with glutamate and with a competitive inhibitor, Glu-hydroxamate, have been detd. to 1.8 .ANG. resoln. The protein fold has structural homol. to other members of the superfamily of N-terminal nucleophile (Ntn) hydrolases, being a sandwich of antiparallel .beta. sheets surrounded by two layers of .alpha. helixes. The structural homol. between the glutaminase domain of GLMS and that of phosphoribosyl pyrophosphate (PRPP) amidotransferase (the only other Ntn amidotransferase whose structure is known) indicates that they may have diverged from a common ancestor. Cysl is the catalytic nucleophile in

GLMS, and the nucleophilic character of its thiol group appears to be increased through general base activation by its own .alpha.-amino group. · Cys1 can adopt two conformations, one active and one inactive; glutamine binding locks the residue in a predetd. conformation. We propose that when a nitrogen acceptor is present Cysl is kept in the active conformation, explaining the phenomenon of substrate-induced activation of the enzyme, and that Arg26 is central in this coupling.

L22 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:

1994:1295 HCAPLUS

DOCUMENT NUMBER:

120:1295

TITLE:

Glucose regulation of transforming growth factor-.alpha. expression is mediated by products of the hexosamine biosynthesis

pathway

AUTHOR(S):

Daniels, Marc C.; Kansal, Preeti; Smith, Tom M.; Paterson, Andrew J.; Kudlow, Jeffrey E.; McClain,

Donald A.

CORPORATE SOURCE:

Veterans Adm. Med. Cent., Birmingham, AL, 35294, USA

SOURCE:

Mol. Endocrinol. (1993), 7(8), 1041-8

CODEN: MOENEN; ISSN: 0888-8809 DOCUMENT TYPE:

Journal

LANGUAGE:

English

The authors have recently shown that glucose and glucosamine regulate the transcription of transforming growth factor -. alpha. (TGF.alpha.) in rat aortic smooth muscle (RASM) cells. Based on the increased potency of glucosamine compared to glucose, the authors hypothesized that stimulation of TGF.alpha. transcription by glucose is mediated through the hexosamine biosynthesis pathway. yeast cDNA for the rate-limiting enzyme of this pathway, glutamine :fructose-6-phosphate

amidotransferase (GFA), was therefore expressed in RASM cells. GFA-transfected cells showed an increase in GFA activity, exhibiting a 2.2-fold increase in the synthesis of glucosamine-6-

phosphate, the first product of the hexosamine biosynthetic pathway. To test the effect of GFA overexpression on TGF.alpha. transcriptional activity, cells were transiently cotransfected with GFA along with a reporter plasmid contq. the firefly luciferase gene under control of the TGF.alpha. promoter. GFA-transfected cells exhibited a glucose-dependent 2-fold increase in TGF.alpha. activity compared to control cells. Maximal stimulation of TGF.alpha. luciferase activity by glucosamine, however, was equiv. in GFA- and control-transfected cells, confirming that the stimulation obsd. by both agents operated through the same pathway. This increase in TGF.alpha. activity was inhibited (85% at 0.5 mM glucose and 69% at 30 mM glucose) by the glutamine analog and inhibitor of GFA, 6-diazo-5-oxonorleucine (10 .mu.M). Control studies confirmed that the increased TGF.alpha.-luciferase activity in the GFA-expressing cells was not an artifact of altered growth, survival, or transfection efficiency. using pharmacol. agents to stimulate or inhibit protein kinase C and cAMP-dependent kinase do not support a role for these second messengers in the signaling pathway. Tunicamycin inhibited the ability of glucose to stimulate TGF.alpha. activity, suggesting that

L22 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 1993:119586 HCAPLUS

DOCUMENT NUMBER:

118:119586

TITLE:

Investigation of the inhibition pathway of

glucosamine synthase by

protein glycosylation does play a role. The authors conclude that

stimulation by glucose of TGF.alpha. in aortic smooth muscle cells.

products of the hexosamine biosynthesis pathway mediate the

N3-(4-methoxyfumaroyl)-L-2,3-diaminopropanoic acid by

semiempirical quantum mechanical and molecular

mechanics methods

AUTHOR(S):

Tarnowska, M.; Oldziej, S.; Liwo, A.; Grzonka, Z.;

Borowski, E.

CORPORATE SOURCE:

Dep. Chem., Univ. Gdansk, Gdansk, PL-80-952, Pol.

SOURCE:

Eur. Biophys. J. (1992), 21(4), 273-80

CODEN: EBJOE8; ISSN: 0175-7571

DOCUMENT TYPE: LANGUAGE:

English

AB Glucosamine 6-phosphate synthase

(EC 2.6.1.16) is a promising target in antifungal drug design. It has been reported that its potent inhibitor, N3-(4-methoxyfumaroy1)-L-2,3-diaminopropanoic acid (FMDP), inactivates the enzyme by the Michael addn. of the SH group to the FMDP mol. followed by cyclization reactions. Here, using semiempirical MNDO, PM3, and mol. mechanics methods, the energetics and kinetic possibility of the formation of various stereoisomers of the products of cyclization of the Michael addn. products detected exptl. were investigated. It was found that the substituted 1,4-thiazin-3-one can be formed in 1 step under alk. conditions; the stereoisomers of this compd., predicted to be the most stable on the basis of theor. calcns., were also the dominant ones in reality.

L22 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:

1990:194297 HCAPLUS

DOCUMENT NUMBER:

112:194297

TITLE:

Glucosamine-6-phosphate

synthase from Escherichia coli: determination

of the mechanism of inactivation by

N3-fumaroyl-L-2,3-diaminopropionic derivatives

Kucharczyk, Nathalie; Denisot, Marie Ange; Le Goffic,

Francois; Badet, Bernard

CORPORATE SOURCE:

Lab. Bioorg. Biotechnol., ENSCP, Paris, 75231, Fr.

SOURCE: Biochemistry (1990), 29(15), 3668-76

CODEN: BICHAW; ISSN: 0006-2960

DOCUMENT TYPE:

Journal English

LANGUAGE:

AUTHOR(S):

A mechanistic investigation of the inactivation of E. coli

glucosamine-6-phosphate synthase by

N3-(4-methoxyfumaroyl)-L-2,3-diaminopropionate (FMDP) was undertaken. the basis of the known participation of the N-terminal cysteine residue in this process, model reactions between FMDP and L-cysteine and between FMDP and the synthetic decapeptide, Cys-Gly-Ile-val-Gly-Ala-Ile-Ala-Gln-Arg, corresponding to the N-terminal protein sequence, were studied. results allowed a pathway to be proposed that was in perfect agreement with the biochem. results: enzyme inactivation arose from Michael addn. of glutamine-binding site cysteine-1 on the fumaroyl double bond at the .beta.-position of the ester group. Upon denaturation under slightly alk. conditions, this adduct underwent cyclization to a transient succinimide adduct, which rearranged into the stable 2-substituted 1,4-thiazin-3-one-5-carboxylate involving participation of the cysteine amino group. The tryptic radiolabeled peptides purified from [3H]FMDP-treated enzyme and resistant to Edman degrdn. coeluted with the products resulting from the model reaction between the synthetic decapeptide and the inhibitor.

L22 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:

1988:146073 HCAPLUS

DOCUMENT NUMBER:

108:146073

TITLE:

Glucosamine synthetase from

Escherichia coli: kinetic mechanism and

inhibition by N3-fumaroy1-L-2,3diaminopropionic derivatives

AUTHOR(S):

Badet, Bernard; Vermoote, Patricia; Le Goffic,

Francois

CORPORATE SOURCE: SOURCE:

Lab. Bioorg. Biotechnol., ENSCP, Paris, 75231, Fr.

Biochemistry (1988), 27(7), 2282-7

CODEN: BICHAW; ISSN: 0006-2960

DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB N3-(4-Methoxyfumaroyl)-L-2,3-diaminopropionic acid (FMDP), a member of a new class of glutamine analogs, was investigated as an **inhibitor** of pure E. coli glucosamine phosphate synthetase (I). **Product**

- and dead-end inhibition studies indicated an ordered assocn. to the enzyme with the sugar mol. binding prior to substrate or inhibitor. The inactivation exhibited pseudo-1st-order kinetics, was irreversible, and occurred faster in the presence of fructose 6-phosphate, a behavior previously reported for the partially purified enzyme from Salmonella typhimurium. FMDP was found to be one of the most efficient inhibitors of I to date. The inhibition occurred with partial covalent incorporation of L-FMDP into I. In the presence of fructose 6-phosphate, enzyme inactivation with [2-3H]-DL-FMDP was assocd. with the incorporation of 0.75 equiv of inhibitor and with the modification of 0.78 SH residue per enzyme subunit. result is the 1st evidence for covalent entrapment of the entire inhibitor mol. following FMDP-mediated I inactivation. Preliminary inactivation with 6-diazo-5-oxo-L-norleucine, known to alkylate selectively the N-terminal cysteine residue, completely prevented radioactivity incorporation. Therefore, this inhibitor is postulated to covalently modify I through direct addn. of the thiol nucleophile from the terminal cysteine residue to the Michaelis acceptor, so acting as an affinity label rather than a mechanism-based inhibitor.

L22 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 1985:204266 HCAPLUS

DOCUMENT NUMBER: 102:204266

TITLE: Synthesis of 3,4-iminocyclohexyl-glycine and its

N-benzyloxycarbonyl derivative

AUTHOR(S): Dzieduszycka, Maria; Martelli, Sante; Borowski, Edward

CORPORATE SOURCE: Dep. Pharm. Technol. Biochem., Tech. Univ. Gdansk,

Gdansk, Pol.

SOURCE: Int. J. Pept. Protein Res. (1985), 25(1),

99-104

CODEN: IJPPC3; ISSN: 0367-8377

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 102:204266

The title compds. I [R = H, PhCH2O2C (Z)] were prepd. from prepd. from cyclohexenylglycines II (R1 = Z, CF3CO) via an addn. reaction with iodine isocyanate (III). Thus, III was added to II (R1 = Z) to give addn. products IV (R2 = Z, R3 = NCO) as a mixt. of the 2 possible 3- and 4-positional isomers. The latter were treated with MeOH to give the corresponding IV (R2 = Z, R3 = NHCO2Me) (as 2 isomers), which were cyclized in the presence of KOH to give I (R = Z). II (R1 = CF3CO) was converted to I (R = H) via IV (R2 = CF3CO, R3 = NHCO2Me). I (R = H) inhibited glucosamine synthetase.